Forxiga
China approves AstraZeneca’s heart failure drug Forxiga
February 4, 2021AstraZeneca, Forxiga
AstraZeneca’s Forxiga (dapagliflozin) has been approved for use in China to reduce the risk of death and hospitalisation from heart …
Japan approves AstraZeneca’s Forxiga for chronic heart failure
November 30, 2020Sales and Marketing AstraZeneca, Forxiga
Japan’s Ministry of Health, Labour and Welfare (MHLW) has announced the authorisation of AstraZeneca’s Forxiga as a treatment for chronic …
AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients
March 25, 2019Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma
AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …
AstraZeneca’s Forxiga displays potential in type 1 diabetes
September 14, 2017Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical
Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
NICE recommends Forxiga in Triple Therapy for Diabetes
October 7, 2016Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes
The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …
NICE recommends Velcade for MCL, and three diabetes drugs
December 23, 2015Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl
NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL). In the …
AstraZeneca scores positive real-world Forxiga data
September 16, 2015Research and Development AstraZeneca, EASD, European Association for the Study of Diabetes, Forxiga, dapagliflozin, exenatide, real world data, real world evidence
The real-world study of AstraZeneca’s diabetes drug Forxiga has found its use in UK patients primary care patients supports the …
AstraZeneca looks for revenue boost via Actavis buy
February 6, 2015Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4
AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …
AstraZeneca ‘simplifies decision-making’
February 4, 2014Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes
AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …
FDA approves Farxiga
January 10, 2014Sales and Marketing AstraZeneca, BMS, FDA, Forxiga, diabetes
The FDA has approved Farxiga, the diabetes treatment developed by AstraZeneca and Bristol-Myers Squibb as part of their soon-to-be-defunct diabetes …
BMS sells diabetes stake to partner AstraZeneca
December 19, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze
AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …
AZ and BMS go for second Forxiga submission
July 29, 2013Sales and Marketing AZ, BMS, FDA, Forxiga
AstraZeneca and partner Bristol-Myers Squibb have resubmitted their diabetes drug Forxiga to the FDA 18 months after it was rejected …
NICE completes Forxiga U-turn
June 26, 2013Sales and Marketing BMS, Forxiga, NICE
Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …
NICE U-turn on Forxiga
May 30, 2013Sales and Marketing Forxiga, NICE
NICE has recommended Bristol-Myers Squibb and AstraZeneca’s diabetes drug Forxiga in final draft guidance after turning its back on the …
NICE rejects Forxiga
February 1, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes
NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
